Gilead's Trodelvy fails to extend survival in lung cancer study, prompting selloff
Fierce Pharma
JANUARY 22, 2024
Even as Gilead looks to become an oncology powerhouse in the coming years, the company on Monday recorded a major setback for its antibody-drug conjugate (ADC) Trodelvy. | The trial outcome marks a setback in Gilead's ambition to grow its presence in the oncology sector.
Let's personalize your content